Baxter International, Inc. Faces Class Action Lawsuit
Levi & Korsinsky, LLP has alerted investors regarding a class action securities lawsuit involving Baxter International, Inc. (NYSE: BAX). This action addresses significant allegations concerning securities fraud that may have affected investors during a specific timeframe.
Understanding the Class Action
The lawsuit aims to recover financial losses incurred by investors adversely affected by alleged misconducts occurring between February 23, 2022 and July 30, 2025. This period marks a crucial time for Baxter International, as claims arise from the company's operations and product performance.
Key Allegations Against Baxter
According to court documents, the allegations include critical points about the safety and effectiveness of Baxter's recent product launch, the Novum LVP. Investors claim that significant defects existed in this product, leading to malfunctions such as underinfusion and overinfusion, which could potentially expose patients to severe risks.
Furthermore, the complaint suggests that Baxter was aware of these defects yet failed to communicate adequately with customers about the dangers associated with the device. This led to further issues, including multiple reports of malfunctions and customer injuries.
What Investors Need to Know
Baxter International, Inc. investors who suffered losses during this timeframe are encouraged to take action quickly. Those interested in participating in the class action have until December 15, 2025, to request to be appointed as lead plaintiffs. It's important to note that participation in any potential recovery does not require you to serve as a lead plaintiff.
Engaging with Legal Representatives
For investors seeking personal assistance, Joseph E. Levi, Esq. actively represents affected parties. You can reach him easily via email or telephone for any inquiries regarding this lawsuit. Transparency and communication are key aspects of navigating such legal nuances.
Cost-Free Participation
A noteworthy aspect of this class action is that for members, compensation comes without the burden of out-of-pocket costs. There is no upfront fee to contribute, ensuring that financial accessibility is maintained throughout the legal process.
Why Choose Levi & Korsinsky?
Levi & Korsinsky boasts a rich history of aiding shareholders in similar circumstances. Over the past two decades, they have secured substantial settlements for investors, demonstrating expertise in complex securities litigation. Their experienced team of over 70 professionals is dedicated to supporting clients in their pursuit of justice.
Contact Information for Legal Support
Investors looking for additional information or needing assistance can contact Levi & Korsinsky at their New York office. Joseph E. Levi and Ed Korsinsky are both available for consultation to guide investors through the process.
Address: Levi & Korsinsky, LLP
33 Whitehall Street, 27th Floor
New York, NY 10004
Telephone: (212) 363-7500
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit concerns allegations of securities fraud affecting investors of Baxter International, Inc. related to product safety issues between February 2022 and July 2025.
How can I participate in the class action?
Investors affected can participate by requesting to be appointed as a lead plaintiff before December 15, 2025, though participation does not require lead plaintiff status.
Are there any costs associated with participating?
No, investors may be entitled to compensation without any out-of-pocket costs or fees.
Why is Levi & Korsinsky leading this case?
Levi & Korsinsky has a strong track record in securities litigation and has recovered significant funds for shareholders over the years.
Who can I contact for more information?
You can reach Joseph E. Levi via email at jlevi@levikorsinsky.com or at (212) 363-7500 for further inquiries.
